Max Mahoney
Senior Director Alamar Biosciences
Seminars
Wednesday 15th April 2026
NULISA Assay Platform – Highest Sensitivity Single- to High-Plex Biomarker Analysis of Soluble Proteins & Fluid Biomarkers in Preclinical Models & for Clinical Development
9:00 am
- NULISA™ combines ultra-sensitive femtogram level detection with barcode-based high-plex biomarker analysis
- Broad matrix compatibility and highest sensitivity in plasma, serum, synovial fluid, nasal lining fluid, sputum, lysates and other matrices
- Single- to five-, and high-plex assays run fully automated on the ARGO HT System
- Custom assay development kits for end-users and CRO development services
- NULISAseq™ Inflammation Panel 250 provides comprehensive analysis of 250 cytokines, chemokines and other immune regulatory proteins from 25uL of biofluid
- NULISAseq Inflammation Panel AQ provides 156 absolute quantification measurements
- NULISAseq Neuro220 Panel is unmatched for high-plex analysis of hundreds of neuroinflammation, vascular, and synaptic dysfunction, and proteinopathy biomarker
- NULISAseq Mouse Panel 120 for disease model analysis of immune, neuro and growth factors
- Unique capability to translate multiplexed discoveries to single and 5-plex biomarker assays with the same antibodies, antigen, and ARGO
- NULISA IVD and ARGO DX in development with funding from Gates Ventures and DxA.
